21st ANNUAL MEETING TO BE HELD MAY 21-25, 2016 IN WASHINGTON, DC, USA
Princeton, NJ—May 16, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced confirmation of key scientific sessions for its 21st Annual International Meeting starting next week, May 21-25, 2016 in Washington, DC, USA. The meeting will feature three, timely Plenary Sessions centered on the theme, “Value, Affordability, and Patient Centeredness: Can We Have It All?”.
First Plenary: Accelerating Cures: Addressing Unmet Patient Need or Putting Patients at Risk? (Monday, May 23, 2016—9:00 AM to 10:30 AM)
This session will feature alternative views on accelerated drug development efforts, as well as the patient view. Speakers will summarize the current status on efforts to accelerate cures globally, highlight outstanding issues and questions under debate, and discuss what the future holds in terms of forthcoming proposals. The session will be moderated by Eleanor M. Perfetto, PhD, MS, Senior Vice President, Strategic Initiatives, National Health Council, Washington, DC and Professor, Pharmaceutical Health Services Research, School of Pharmacy, University of Maryland, Baltimore, MD, USA. Speakers include Jerry Avorn, MD, Professor of Medicine, Harvard Medical School and Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; Scott Gottlieb, MD, Resident Fellow, American Enterprise Institute, Washington, DC, USA; and Patricia Furlong, Founding President and Chief Executive Officer, Parent Project Muscular Dystrophy (PPMD), Middletown, OH, USA. Additional information on the plenary can be found here.
Second Plenary: Making Medical Decisions in an Irrational World (Tuesday, May 24, 2016—9:00 AM to 10:30 AM)
This session will focus on emerging behavioral economic models and examine their potential to influence the future design of health plans. Speakers will explore the biologic and experimental evidence over the past four decades that suggests that current decision- and cost-effectiveness analyses used to guide resource allocation options (that are grounded in neo-classical economic theory) may be inconsistent with human preferences and behaviors. The plenary will be moderated by Bradley C. Martin, PharmD, RPh, PhD, Professor and Head, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA. Speakers include Kevin Volpp, MD, PhD, Director, Center for Health Incentives and Behavioral Economics, Leonard Davis Institute Vice Chair, Health Policy, Department of Medical Ethics and Health Policy Professor, Medicine and Health Care Management, University of Pennsylvania, Philadelphia, PA, USA; Douglas E. Hough, PhD, Associate Scientist, Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA; and David Meltzer, MD, PhD, Fannie L. Pritzker Professor of Medicine, Economics, and Public Policy, Chief of the Section of Hospital Medicine, Director of the Center for Health and the Social Sciences, and Chair of the Committee on Clinical and Translational Science, University of Chicago, Chicago, IL, USA. Additional information on this plenary can be found here.
Third Plenary: Contemporary Regulatory and Legislative Issues in Health Outcomes Research (Wednesday, May 25, 2016—10:15 AM to 11:30 AM)
This plenary will feature speakers from the US Food and Drug Administration, the pharmaceutical industry, patient advocacy, and a policy think tank. The plenary speakers will explore current regulatory and legislative issues affecting health outcomes research, including patient-centered research and development, the promotion of health economic claims, and the role of regulatory oversight in a dynamic health care environment. The session will be moderated by Daniel Malone, PhD, RPh, ISPOR President and Professor of Pharmacy, College of Pharmacy and Associate Professor, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA. Speakers include Theresa M. Mullin, PhD, Director, Office of Strategic Programs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA; Marc M. Boutin, JD, Chief Executive Officer, National Health Council, Washington, DC, USA; Gregory W. Daniel, PhD, MPH, RPh, Deputy Director, Duke-Robert J. Margolis, MD Center for Health Policy, Duke University, Washington, DC, USA; and Kay Holcombe, MS, Senior Vice President, Science Policy, BIO, Washington, DC, USA. Additional information on this plenary can be found here.
The 21st Annual International Meeting also features more than 1,800 presentations, including a wide variety of issue panels, forums, workshops, and educational symposia. The ISPOR Short Course Program will be held immediately preceding the meeting (Saturday, May 21 and Sunday, May 22) offers 30 HEOR courses in seven tracks that range from introductory to advanced levels. Registration is currently open for the meeting and additional information can be found here.